Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
Authors: Hassaniazad Mehdi , Bazram Ali , Hassanipour Soheil , Fathalipour Mohammad 
Published: October 2020

Abstract
Objectives
We will evaluate the efficacy and safety of favipiravir and interferon beta-1a compared to lopinavir/ritonavir and interferon beta-1a in patients with confirmed COVID-19, who are moderately ill.

Trial design
This is a phase 3, single-center, randomized, open-label, controlled trial with a parallel-group design carried out at Shahid Mohammadi Hospital, Bandar Abbas, Iran.

Participants
All patients with age ≥ 20 years admitted at the Severe Acute Respiratory Syndrome Departments of the Shahid Mohammadi Hospital, Bandar Abbas, Iran, will be screened for the following criteria.
Inclusion criteria:

Confirmed diagnosis of infection with SARS-CoV-2 using polymerase chain reaction and/or antibody tests.

Moderate COVID-19 pneumonia (via computed tomography and/or X-ray imaging), requiring hospitalization.

Hospitalized ≤ 48 h.

Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.

Exclusion criteria:

Underlying conditions, including chronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, peptic ulcers, acute and chronic renal failure, and peptic ulcers.

Severe and critical COVID-19 pneumonia.

History of allergy to favipiravir, lopinavir/ritonavir, and interferon beta-1a.

Pregnancy and breastfeeding.

Intervention and comparator
Intervention group: favipiravir (Zhejiang Hisun, China) with interferon beta-1a (CinnaGen, Iran). This group will receive 1600 mg favipiravir twice a day for the first day and 600 mg twice a day for the following 4 days with five doses of 44 mcg interferon beta-1a every other day.
Control group: lopinavir/ritonavir (Heterd Company, India) with interferon beta-1a (CinnaGen, Iran). This group will receive 200/50 mg lopinavir/ritonavir twice a day for 7 days with five doses of 44 mcg interferon beta-1a every other day.
Other supportive and routine care will be the same in both groups.

Main outcomes
The primary outcome of the trial is the viral load of SARS-CoV-2 in the nasopharyngeal samples assessed by RT-PCR after 7 days of randomization as well as clinical improvement of fever and O2 saturation within 7 days of randomization.
The secondary outcomes are the length of hospital stay and the incidence of serious adverse drug reactions within 7 days of randomization.

Randomization
Eligible patients will be allocated to one of the study arms using block randomization in a 1:1 ratio (each block consists of 10 patients). A web-based system will be used to generate random numbers for the allocation sequence. Each number relates to one of the study arms.

Blinding (masking)
This is an open-label trial without blinding and placebo control.

Numbers to be randomized (sample size)
A total of 60 patients will be randomized into two groups (30 patients in the intervention group and 30 patients in the control group).

Trial status
The trial protocol is version 1.0, 22 July 2020. Recruitment began on 25 July 2020 and is anticipated to be completed by 25 September 2020.

Trial registration
Iranian Registry of Clinical Trials (IRCT) IRCT20200506047323N3. Registered on 22 July 2020.

Full protocol
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.